Ensuring Access to Optimal Therapy in CF: The ENACT Study

Recruiting Phase 4 Interventional Study
Cystic Fibrosis (CF)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
3 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
Arkansas Children's Hospital Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treat…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype * age 2 years and older * ability to provide written informed consent and/or assent (by subject and/or legal guardian) * on a stable dose of triple combination CFTR modulator therapy for at least…
Contacts

Jennifer S Guimbellot, Medical Degree and License

501-364-5365

jguimbellot@uams.edu

CONTACT

Michelle Gillespie

501-364-3377

GillespieM@archildrens.org

CONTACT